Insilico Medicine’s rentosertib shows potential to slow aging in landmark Phase III trial

A drug that was conceived by artificial intelligence, designed in roughly 18 months, and showed striking improvements in lung function is now in its final stretch of human testing. Insilico Medicine’s rentosertib, the first oral TNIK inhibitor to reach clinical trials, began Phase III testing on July 7, 2026, across 47 centers in China with approximately 320 patients enrolled. The stakes are unusually high. Rentosertib isn’t just targeting idiopathic pulmonary fibrosis (IPF), a progressive and often fatal lung disease with limited treatment options. Its mechanism of action goes after cellular senescence itself, the biological process underpinning much of what we call aging. The numbers that got everyone’s attention Phase IIa results, published in Nature Medicine in June 2025, told a compelling story. Patients receiving the 60 mg dose of rentosertib saw a mean increase of 98.4 mL in forced vital capacity (FVC) over 12 weeks. The placebo group, by contrast, experienced a decrease of 20.3 mL. The drug also demonstrated what researchers described as a manageable safety profile. In a disease space where existing therapies like nintedanib and pirfenidone merely slow decline and come with...